Track Unicycive Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Unicycive Therapeutics Inc. Common Stock UNCY · Stock Open Unicycive Therapeutics Inc. Common Stock in new tab

3.53 USD
EPS
-1.72
P/B
1.86
ROE
-101.07
Beta
1.86
Target Price
28.40 USD
Loading chart...
Key Metrics
Earnings dateNov. 18, 2026
EPS-1.72
Book Value1.91
Price to Book1.86
Debt/Equity1.26
% Insiders2.969%
Estimates
Forward P/E2.45
Forward EPS1.45
Target Mean Price28.40

DCF valuation

Model fair value for Unicycive Therapeutics Inc. Common Stock (UNCY)
Result
Sign in to run the valuation for UNCY.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus None · mean target 28.40 USD (low 13.00, high 42.00) · as of 14 Nov 2026
Low 13.00
Mean 28.40
High 42.00
Price 3.53
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Unicycive Therapeutics Inc. Common Stock Logo Unicycive Therapeutics Inc. Common Stock Analysis (UNCY)

United States Health Care Official Website Stock

Is Unicycive Therapeutics Inc. Common Stock a good investment? Unicycive Therapeutics Inc. Common Stock (UNCY) is currently trading at 3.53 USD. Market analysts have a consensus price target of 28.40 USD. This suggests a potential upside from current levels.

Earnings Schedule: Unicycive Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 18, 2026. The market consensus estimate for Forward EPS is 1.45.

Investor FAQ

Does Unicycive Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Unicycive Therapeutics Inc. Common Stock?

Unicycive Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of -1.72.

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Exchange Ticker
NMS (United States) UNCY
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 20, 2025 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion